Search results
Results from the WOW.Com Content Network
A large-scale study in Buenos Aires from December 29, 2020, to May 15, 2021, with 663,602 participants aged 60 and older who received Spunik V, the Oxford–AstraZeneca vaccine, or the Sinopharm BIBP vaccine observed an overall efficacy of 98% (95% CI, 95 – 99%) against COVID-19-related deaths. The study noted that the three vaccines showed a ...
Moderna has launched a trial of a vaccine to tackle the Beta variant or lineage B.1.351. [460] On 17 February 2021, Pfizer announced neutralization activity was reduced by two-thirds for this variant, while stating that no claims about the efficacy of the vaccine in preventing illness for this variant could yet be made. [461]
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
Pfizer and Moderna vaccines are both safe and have similar effectiveness at preventing COVID-19 illness. Clinical trial data when they were first released in December 2020 showed 95% efficacy for ...
Russia was quick to develop its two-dose Sputnik V vaccine last year and has also deployed a one-shot Sputnik Light vaccine, both of which have it says demonstrated high efficacy in trials, but ...
Public scepticism continues to exist despite Russian and Western sources detailing the positive efficacy of the vaccine. [43] A study in 2017 indicated that anti-vaccine views had been present in Russia prior to the pandemic, which only increased after the pandemic emerged.
The Sputnik V was later approved for use on 23 March 2021. [5] The Sinopharm BIBP vaccine was approved for emergency use on 4 June 2021, [6] while Pfizer–BioNTech COVID-19 vaccine, Moderna COVID-19 vaccine and Janssen COVID-19 vaccine were approved on 12 June 2021, [7] 29 June 2021, [8] [9] and 15 July 2021, [10] [11] respectively.
Retrospective cohort study of the effectiveness of two Russian vaccines against the SARS-CoV-2 Delta variant in Moscow (June–July 2021) proved that EpiVacCorona, unlike Sputnik V, is an ineffective vaccine and therefore cannot protect against COVID-19. [4]